Antiemetic Therapy in Older Cancer Patients

• Yancik R , RiesL: Aging and cancer in America.Hematol. Oncol. Clin. North Am.14, 17–23(2000).
   PubMed Web of Science ®Google Scholar
• Yancik R , RiesL: Cancer in older persons: an international issue in an aging world.Semin. Oncol.32, 128–136(2004).
   Google Scholar
• Hutchins LF , UngerJM, CrowleyJJet al.: Underrepresentation of patients over 65 years of age or older in cancer-treatment trials.N. Engl. J. Med.341, 2061–2067(1999).
   PubMed Web of Science ®Google Scholar
• Yee KWL , PaterJL, PhoL, ZeeB, SiuLL: Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?J. Clin. Oncol.21, 1618–1623(2003).
   PubMed Web of Science ®Google Scholar
• Aapro MS , Kohne C-H, Cohen HJ, Extermann M: Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist10(3), 198–204(2005).
   PubMed Web of Science ®Google Scholar
• Vaessen G : Optimising antiemetic treatment – nurse survey results.3rd European Oncology Nursing Society Spring Convention, Venice, Italy, 3–11 April (2002).
   Google Scholar
• Doherty KM : Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy.Clin. J. Oncol. Nurs.3, 113–119(1999).
   PubMedGoogle Scholar
• Schnell FM : Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control.Oncologist8, 187–198(2003).
   PubMed Web of Science ®Google Scholar
• Watter JM , McClaranJC, Man-Son-Hing M: The elderly surgical patient. In: ACS Surgery: Principles and Practice. WebMD Professional Publishing, NY, USA (2004).
   Google Scholar
• Cheitlin MD : Cardiovascular physiology – changes with aging.Am. J. Geriatr. Cardiol.12, 9–13(2003).
   PubMedGoogle Scholar
• Lichtman SM , VillaniG: Chemotherapy in the elderly: pharmacologic considerations.Cancer Control7, 548–556(2000).
   PubMedGoogle Scholar
• Massoud N : Pharmacokinetic considerations in geriatric patients. In:Pharmacokinetic Basis for Drug Treatment. Benet LZ, Massoud N, Gambertoglio JG (Eds). Raven Press, NY, USA, 283–310(1984).
   Google Scholar
• Gridelli C , PerroneF, GalloCet al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomised trial.J. Natl Cancer Inst.95, 362–372(2003).
   PubMed Web of Science ®Google Scholar
• Jorgensen T , JohanssonS, KennerfalkA, WallanderMA, SvardsuddK: Prescription drug use, diagnoses, and healthcare utilization among the elderly.Ann. Pharmacother.35, 1004–1009(2001).
   PubMed Web of Science ®Google Scholar
• Bedell SE , JabbourS, GoldbergRet al.: Discrepancies in the use of medications: their extent and predictors in an outpatient practice.Arch. Intern. Med.160, 2129–2134(2000).
   PubMed Web of Science ®Google Scholar
• Ernst E : Prevalence of use of complementary/alternative medicine: a systematic review.Bull. World Health78, 252–257(2000).
   PubMed Web of Science ®Google Scholar
• Schindler JS , KellyJH: Swallowing disorders in the elderly.Laryngoscope112, 589–602(2002).
   PubMed Web of Science ®Google Scholar
• Hall KE : Aging and neural control of the GI tract. II. Neural control of the aging gut: can an old dog learn new tricks?Am. J. Physiol. Gastrointest. Liver Physiol.283, G827–G832 (2002).
   PubMed Web of Science ®Google Scholar
• Makins R , BallingerA: Gastrointestinal side effects of drugs.Expert Opin. Drug Saf.2, 421–429(2003).
   PubMedGoogle Scholar
• Park HL , O‘ConnellJE, ThomsonRG: A systematic review of cognitive decline in the general elderly population.Int. J. Geriatr. Psychiatry18, 1121–1134(2003).
   PubMed Web of Science ®Google Scholar
• Grunberg SM , HansenM, DeusonR, MavrosP: Incidence and impact of nausea/vomiting with modern antiemetics: perception vs. reality.Proc. Am. Soc. Clin. Oncol.21, A996 (2002).
   Google Scholar
• Glaus A , KnippingC, MorantRet al.: Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.Support Care Cancer12, 708–715(2004).
   PubMed Web of Science ®Google Scholar
• Kenney WL , ChiuP: Influence of age on thirst and fluid intake.Med. Sci. Sports Exerc.33, 1524–1532(2001).
   PubMed Web of Science ®Google Scholar
• Gralla RJ , OsobaD, KrisMGet al.: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. An ASCO special article.J. Clin. Oncol.17, 2971–2994(1999).
   PubMed Web of Science ®Google Scholar
• Koeller JM , AaproMS, GrallaRJet al.: Antiemetic guidelines: creating a more practical treatment approach.Support. Care Cancer10, 519–522(2002).
   PubMed Web of Science ®Google Scholar
• Kris MG , HeskethPJ, HerrstedtJet al.: Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.Support.Care Cancer13, 85–96(2005).
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S , Rodrigues-PerieiraJ, Carides AD et al.: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer97, 3090–3098(2003).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ , GrunbergSM, GrallaRJet al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multidimensional, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group.J. Clin. Oncol.21, 4112–4119(2003).
   PubMed Web of Science ®Google Scholar
• Balducci L , YatesJ: General guidelines for the management of older patients with cancer.Oncology (Williston Park)14(11A), 221–227(2000).
   PubMed Web of Science ®Google Scholar
• Aapro MS , MacciocchiA, GridelliC: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.J. Support Oncol.3, 369–374(2005).
   PubMedGoogle Scholar
• ASHP: ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. Health Syst. Pharm.56, 729–764(1999).
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann. Oncol.6, 805–810(1995).
   PubMed Web of Science ®Google Scholar
• Ruff P , PaskW, GoedhalsLet al.: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study.Oncology51, 113–118(1994).
   PubMed Web of Science ®Google Scholar
• Gralla R , LichinitserM, Van der Vegt S et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol.14, 1570–1577(2003).
   PubMed Web of Science ®Google Scholar
• Eisenberg P , Figueroa-VadilloJ, ZamoraRet al.: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer98, 2473–2482(2003).
   PubMed Web of Science ®Google Scholar
• Blower PR : 5-HT3-receptor antagonists – receptor interaction and implications for duration of antiemetic effect.17th International MASCC/ISOO Symposium, Geneva, Switzerland, 30 June–2 July (2005).
   Google Scholar
• Zofran® tablets (ondansetron hydrochloride), product information. Glaxo Wellcome Inc., Research Triangle Park, NC, USA (2001).
   Google Scholar
• Anzemet® tablets (dolasetron mesylate), prescribing information. Aventis Pharmaceuticals, Kansas City, MO, USA (2000).
   Google Scholar
• Navoban® (tropisetron), product information. Novartis Pharmaceuticals Australia Pty Ltd., North Ryde, NSW, Australia (1997).
   Google Scholar
• Kytril® (granisetron hydrochloride), prescribing information. Roche Laboratories Inc., Nutley, NJ, USA (2000).
   Google Scholar
• Piraccini G , GallagherS, MacchiocchiA: Palonosetron: a phase II dose ranging study to assess, over a 7-day period, the single-dose pharmacokinetic profile of palonosetron in patients receiving highly emetogenic chemotherapy.Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 449).
   Google Scholar
• Newberry NR , WatkinsCJ, SprosenTSet al.: BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology32, 729–735(1993).
   PubMed Web of Science ®Google Scholar
• Boeijinga PH , GalvanM, BaronBMet al.: Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108–15 neuroblastoma x glioma cells.Eur. J. Pharmacol.219, 9–13(1992).
   PubMed Web of Science ®Google Scholar
• Aloxi® summary of product characteristics, Cambridge Laboratories Ltd, Tyne & Wear, UK (2005).
   Google Scholar
• de Alwis DP , AaronsL, PalmerJL: Population pharmacokinetics of ondansetron: a covariate analysis.Br. J. Clin. Pharmacol.46(2), 117–125(1998).
   PubMed Web of Science ®Google Scholar
• van Wijingaarden I , TulpM, SoudijinW: The concept of selectivity in 5-HT receptor research.Eur. J. Pharmacol.138, 301–312(1990).
   Google Scholar
• Wong EH , ClarkR, LeungEet al.: The interaction of RS 25259–197, a potent and selective antagonist, with 5-HT3 receptors in vitro.Br. J. Pharmacol.114, 851–859(1995).
   PubMed Web of Science ®Google Scholar
• Perez EA , HeskethP, SandbachJet al.: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.J. Clin. Oncol.16, 754–760(1998).
   PubMed Web of Science ®Google Scholar
• Lofters WS , PaterJL, ZeeBet al.: Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.J. Clin. Oncol.15, 2966–2673(1997).
   PubMed Web of Science ®Google Scholar
• Chey WD , CashBD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin. Investig. Drugs14(2), 185–193(2005).
   PubMed Web of Science ®Google Scholar
• Lievre M : Alosetron for irritable bowel syndrome.Br. Med. J.325(7364), 555–556(2002).
   PubMedGoogle Scholar
• Higgins PD , JohansonJF: Epidemiology of constipation in North America: a systematic review.Am. J. Gastroenterol.99(4), 750–759(2004).
   PubMed Web of Science ®Google Scholar
• Gharib MI , BurnettAK: Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Eur. J. Heart Fail.4(3), 235–242(2002).
   PubMed Web of Science ®Google Scholar
• Adams MJ , LipshultzSE, SchwartzC, FajardoLF, CoenV, ConstineLS: Radiation-associated cardiovascular disease: manifestations and management.Semin. Radiat. Oncol.13(3), 346–356(2003).
   PubMed Web of Science ®Google Scholar
• Gilbar PJ , BrodribbTR: Phenytoin and fluorouracil interaction.Ann. Pharmacother.35, 1367–1370(2001).
   PubMed Web of Science ®Google Scholar
• Grossman SA , HochbergF, FisherJet al.: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS consortium. The new approaches to brain tumor therapy.Cancer Chemother. Pharmacol.42, 118–126(1998).
   PubMed Web of Science ®Google Scholar
• Le AT , HassonNK, LumBL: Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy.Ann. Pharmacother.31, 1006–1008(1997).
   PubMed Web of Science ®Google Scholar
• Scarfe MA , IsraelMK: Possible drug interaction between warfarin and combination of levamisole and fluorouracil.Ann. Pharmacother.28, 464–467(1994).
   PubMed Web of Science ®Google Scholar
• Onoda S , MitsufujiH, YanaseNet al.: Drug interaction between gefitinib and warfarin.Jpn J. Clin. Oncol.35, 478–482(2005).
   PubMed Web of Science ®Google Scholar
• Tobe SW , SiuLL, JamalSAet al.: Vinblastine and erythromycin: an unrecognized serious drug interaction.Cancer Chemother. Pharmacol.35, 188–190(1995).
   PubMed Web of Science ®Google Scholar
• Bosque E : Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.Ann. Intern. Med.134, 427 (2001).
   PubMed Web of Science ®Google Scholar
• Hebbard GS , SmithKG, GibsonPRet al.: Augmentin-induced jaundice with a fatal outcome.Med. J. Aust.156, 285–286(1992).
   PubMed Web of Science ®Google Scholar
• Blower PR : 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.Cancer J.8(5), 405–414(2002).
   PubMed Web of Science ®Google Scholar
• Firkusny L , KroemerHK, EichelbaumM: In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron.Biochem. Pharmacol.49, 1777–1784(1995).
   PubMed Web of Science ®Google Scholar
• Kaiser R , SezerO, PapiesAet al.: Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.J. Clin. Oncol.20, 2805–2811(2002).
   PubMed Web of Science ®Google Scholar
• Kim M -K, Cho J-Y, Lim H-S et al.: Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur. J. Clin. Pharmacol.59, 111–116(2003).
   PubMed Web of Science ®Google Scholar
• Stanford BJ , StanfordSC: Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?J. Psychopharmacol.13(3), 313–317(1999).
   PubMed Web of Science ®Google Scholar
• De Witte JL , SchoenmakersB, SesslerDIet al.: The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth. Analg.92, 1319–1321(2001).
   PubMed Web of Science ®Google Scholar
• Cagnoni PJ , MatthesS, DayTCet al.: Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.Bone Marrow Transplant.24, 1–4(1999).
   PubMed Web of Science ®Google Scholar
• Gilbert CJ , PetrosWP, VrendenburghJet al.: Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.Cancer Chemother. Pharmacol.42, 497–503(1998).
   PubMed Web of Science ®Google Scholar
• Blum RA , MajumdarA, McCreaJet al.: Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.Clin. Ther.25, 1407–1419(2003).
   PubMed Web of Science ®Google Scholar
• de Wit R , HerrstedtJ, RapoportBet al.: The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.Eur. J. Cancer40, 403–410(2004).
   PubMed Web of Science ®Google Scholar
• Bauwens G , AaproMS, PendergrassKet al.: The oral NK1 receptor antagonist aprepitant is effective for the prevention of chemotherapy induced nausea and vomiting in elderly patients receiving high-dose cisplatin.Proc. Am. Soc. Clin. Oncol.22, 786 (2003) (Abstract 3159).
   Google Scholar
• Campos D , PereiraJR, ReinhardtRRet al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.J. Clin. Oncol.19, 1759–1767(2001).
   PubMed Web of Science ®Google Scholar
• Emend® (aprepitant), prescribing information. Merck & Co, Inc., Whitehouse Station, NJ, USA (2005).
   Google Scholar
• Chawla SP , GrunbergSM, GrallaRJet al.: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Cancer97, 2290–2300(2003).
   PubMed Web of Science ®Google Scholar
• Shadle CR , LeeY, MajumdarAKet al.: Evaluation of potencial inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.J. Clin. Pharmacol.44, 215–223(2004).
   PubMed Web of Science ®Google Scholar
• Majumdar AK , McCreaJB, PanebiancoDLet al.: Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.Clin. Pharmacol. Ther.74, 150–156(2003).
   PubMed Web of Science ®Google Scholar
• Sanchez RI , WangRW, NewtonDJet al.: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant.Drug Metab. Dispos.32, 1287–1292(2004).
   PubMed Web of Science ®Google Scholar
• Depre M , Van Hecken A, Oeyen M et al.: Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur. J. Clin. Pharmacol.61, 341–346(2005).
   PubMed Web of Science ®Google Scholar
• McCrea JB , MajumdarAK, GoldbergMRet al.: Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methyprednisolone.Clin. Pharmacol. Ther.74, 17–24(2003).
   PubMed Web of Science ®Google Scholar
• Mertens  WC, Higby DJ, Brown D et al.: Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J. Clin. Oncol.21(7), 1373–1378(2003).
   PubMed Web of Science ®Google Scholar
• Gridelli C , MaioneP, RossiA: Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?J. Clin. Oncol.21, 4066–4069(2003).
   PubMed Web of Science ®Google Scholar
• Vardy JL , ChiewK, GalicaJet al.: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.Proc. Am. Soc. Clin. Oncol.23, 733 (2005) (Abstract 8017).
   Web of Science ®Google Scholar
• Aapro M : Profiling the ideal antiemetic for elderly cancer patients: should we challenge ‘delayed phase’ steroids‘?5th International Society of Geriatric Oncology (SIOG) Meeting, San Francisco, CA, USA, 15–16 October (2004) (Abstract 35).
   Google Scholar
• Gridelli C : Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics.Drugs Aging21, 825–832(2004).
   PubMed Web of Science ®Google Scholar
• Terret C , AlbrandG, DrozJP: Multidimensional Geriatric Assessment reveals unknown medical problems in elderly cancer patients (pts).J. Clin. Oncol.22(Suppl. 14), 8167 (2004).
   Web of Science ®Google Scholar
• Extermann M , AaproM, BernabeiRet al.: Task Force on CGA of the International Society of Geriatric Oncology: use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).Crit. Rev. Oncol. Hematol.55, 241–252(2005).
   PubMed Web of Science ®Google Scholar
• Balducci L : New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care.J. Support Oncol.1(4 Suppl. 2), 30–37(2003).
   PubMedGoogle Scholar
• Huynh T , Sanchez-ReillyS, KarnadA: Assessing the need for a Geriatric Oncology Assessment Clinic: a successful partnership among specialties.Proc. Am. Soc. Clin. Oncol.23, S795 (2005) (Abstract 8268).
   Web of Science ®Google Scholar

Websites

• Multinational Association for Supportive Care in Cancer (MASCC), 2005 www.mascc.org/ktml2/images/uploads/Resource_centers/MASCC_Guidelines_Update_9_05.pdf Accessed November2005
   Google Scholar
• British National Formulary www.bnf.org/bnf/
   Google Scholar